Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out, and the correlation of expression with disease variables and clinical outcome will be assessed. This will be done retrospectively using archived hepatocellular carcinoma tissue samples.
Study Type
OBSERVATIONAL
Enrollment
200
Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
GSK Investigational Site
Taipei, Taiwan
GSK Investigational Site
Bangkok, Thailand
GSK Investigational Site
Chiang Mai, Thailand
The proportion of hepatocellular carcinoma patients whose tumor tissue expresses specific tumor antigens.
Time frame: At the time of analysis
The prognostic character of the expression of the tumor antigens
Time frame: At the time of analysis
Expression of c-MET in the same hepatocellular carcinoma tumor samples
Time frame: At the time of analysis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.